Michele Magnino, MD
Dermatology · Fairfax, VANPI 1497173512
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Johnson & Johnson at 37.9% of the total. 2025 is the largest year on record at $16,809, more than ten times the $364 reported in 2019. Among dermatology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 489 payments — averaging $67.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$13K
- E.r. Squibb & Sons, L.L.C.$8K
- AbbVie$5K
- Incyte Corporation$2K
- Lilly USA, LLC$765
- LEO Pharma Inc.$737
- plus $4K from 23 others
What the payments were for
- Consulting fees$8,02624%
- Speaking & faculty fees$8,66326%
- Travel & lodging$2,6378%
- Food & beverage$13,58741%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $12,502 |
| E.r. Squibb & Sons, L.L.C. | 50 | $8,235 |
| AbbVie(2 entities) | 79 | $4,680 |
| Incyte Corporation | 69 | $1,865 |
| Lilly USA, LLC | 21 | $765 |
| LEO Pharma Inc. | 31 | $737 |
| Regeneron Healthcare Solutions, Inc. | 25 | $701 |
| Novartis | 30 | $614 |
| UCB, Inc. | 22 | $526 |
| Janssen Scientific Affairs, LLC | 3 | $364 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 19 | $340 |
| Pfizer | 13 | $279 |
| Sun Pharmaceutical Industries Inc. | 10 | $232 |
| Amgen | 7 | $219 |
| Galderma Laboratories, L.p. | 9 | $168 |
| Dermavant Sciences, Inc. | 7 | $146 |
| Sanofi | 4 | $107 |
| Organon | 5 | $101 |
| EPI Health, LLC | 5 | $94 |
| Journey Medical Corporation | 1 | $64 |
| Strata Skin Sciences, Inc. | 3 | $52 |
| Arcutis Biotherapeutics, Inc. | 3 | $48 |
| Almirall LLC | 3 | $41 |
| VYNE Pharmaceuticals Inc. | 2 | $32 |
| Botanix SB Inc | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Dermira, Inc. | 1 | $21 |
| Mayne Pharma Commercial LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,030 in reported general payments places this provider in the 90th percentile of 396 dermatology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 15 | $312,352 |
| OtezlaApremilast | 25 | $119,402 |
| Dupixent PenDupilumab | 14 | $52,206 |
| OpzeluraRuxolitinib Phosphate | 14 | $26,932 |
| JubliaEfinaconazole | 16 | $16,558 |
| ZoryveRoflumilast | 11 | $10,117 |
| Clobetasol Propionate | 116 | $6,545 |
| Calcipotriene | 19 | $2,222 |
| Pimecrolimus | 12 | $1,825 |
| Doxycycline Hyclate | 40 | $1,725 |
| Econazole Nitrate | 36 | $1,595 |
| Fluorouracil | 24 | $1,545 |
| Tretinoin | 15 | $1,376 |
| Hydroxychloroquine Sulfate | 23 | $1,129 |
| Desonide | 37 | $1,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $219 | $119,40225 claims |
| Incyte CorporationOpzelura | $1,865 | $26,93214 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia | $340 | $16,55816 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $48 | $10,11711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 396 dermatology providers in Virginia.
Other dermatology in Fairfax
- Saurabh SinghFairfax$1.7M
- Hema SundaramFairfax$181K
- Jennifer DesimoneFairfax$82K
- Naiem IssaVienna$2M
- Diego DasilvaVirginia Beach$1.1M
- Vishal PatelLeesburg$719K
- Cyndi Torosky TommasoVirginia Beach$717K
- Daniel HurdBlacksburg$545K
- Jonathan SchreiberNorfolk$330K
- Robert BaerSuffolk$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.